{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:50:47Z","timestamp":1784631047128,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biological treatment and treat-to-target approaches guide the achievement of inactive disease and clinical remission in Autoinflammatory Diseases (AID). However, there is limited evidence addressing optimal tapering strategies and\/or discontinuation of biological treatment in AID. This study evaluates available evidence of tapering biological treatment and explores key factors for successful tapering.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic literature search was conducted in Embase, MEDLINE, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials using the OVID platform (1990-08\/2020). Bibliographic search of relevant reviews was also performed. Studies\/case series (n\u2009\u2265\u20095) in AID patients aged\u2009\u2264\u200918 years with biological treatment providing information on tapering\/treatment discontinuation were included. After quality assessment aggregated data were extracted and synthesized. Tapering strategies were explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 6035 records were identified. Four papers were deemed high quality, all focused on systemic juvenile idiopathic arthritis (sJIA) (1 open-label randomized trial, 2 prospective, 1 retrospective observational study). Biological treatment included anakinra (<jats:italic>n<\/jats:italic>\u2009=\u20092), canakinumab (<jats:italic>n<\/jats:italic>\u2009=\u20091) and tocilizumab (<jats:italic>n<\/jats:italic>\u2009=\u20091). Strategies in anakinra tapering included alternate-day regimen. Canakinumab tapering was performed randomized for dose reduction or interval prolongation, whereas tocilizumab was tapered by interval prolongation. Key factors identified included early start of biological treatment and sustained inactive disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tapering of biological treatment after sustained inactive disease should be considered. Guidance for optimal strategies is limited. Future studies may leverage therapeutic drug monitoring in combination with pharmacometric modelling to further enhance personalized \u201ctaper-to-target\u201d strategies respecting individual patients and diseases aspects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-022-00725-3","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T07:15:54Z","timestamp":1660374954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tapering of biological treatment in autoinflammatory diseases: a scoping review"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-0327","authenticated-orcid":false,"given":"Tatjana","family":"Welzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Oefelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinka","family":"Twilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin B.","family":"Kuemmerle-Deschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Benseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"issue":"1","key":"725_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.iac.2018.08.004","volume":"39","author":"L Broderick","year":"2019","unstructured":"Broderick L. Hereditary Autoinflammatory Disorders: Recognition and Treatment. Immunol Allergy Clin North Am. 2019;39(1):13\u201329.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"725_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.berh.2017.12.001","volume":"31","author":"HJ Lachmann","year":"2017","unstructured":"Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol. 2017;31(4):596\u2013609.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"725_CR3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/annrheumdis-2016-210092","volume":"76","author":"NM Ter Haar","year":"2017","unstructured":"Ter Haar NM, Annink KV, Al-Mayouf SM, Amaryan G, Anton J, Barron KS, et al. Development of the autoinflammatory disease damage index (ADDI). Ann Rheum Dis. 2017;76(5):821\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"725_CR4","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F De Benedetti","year":"2018","unstructured":"De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018;378(20):1908\u201319.","journal-title":"N Engl J Med"},{"issue":"23","key":"725_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. N Engl J Med. 2009;360(23):2416\u201325.","journal-title":"N Engl J Med"},{"issue":"5","key":"725_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"725_CR7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","volume":"74","author":"NM ter Haar","year":"2015","unstructured":"ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"725_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"725_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12969-020-0409-3","volume":"18","author":"S Hansmann","year":"2020","unstructured":"Hansmann S, Lainka E, Horneff G, Holzinger D, Rieber N, Jansson AF, et al. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD\/HIDS: a German PRO-KIND initiative. Pediatr Rheumatol Online J. 2020;18(1):17.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"725_CR10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40744-021-00331-x","volume":"8","author":"LR Grazziotin","year":"2021","unstructured":"Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, et al. Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatol Ther. 2021;8(3):1303\u201322.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"725_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139, W64.","journal-title":"Ann Intern Med"},{"issue":"12","key":"725_CR12","first-page":"1290","volume":"28","author":"M van Tulder","year":"2003","unstructured":"van Tulder M, et al. Updated methods Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review Group. Spine. 2003;28(12):1290\u20139.","journal-title":"Spine."},{"key":"725_CR13","unstructured":"Phillips B. Oxford Center for Evidence-based Medicine. Levels of Evidence, March 2009http:\/\/www.cebm.net\/index.aspx?o=1025. 2009."},{"issue":"11","key":"725_CR14","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290\u20134.","journal-title":"J Rheumatol"},{"issue":"12","key":"725_CR15","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1136\/annrheumdis-2013-203666","volume":"73","author":"M Piram","year":"2014","unstructured":"Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73(12):2168\u201373.","journal-title":"Ann Rheum Dis"},{"key":"725_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1546-0096-13-4","volume":"13","author":"MM Kostik","year":"2015","unstructured":"Kostik MM, Dubko MF, Masalova VV, Snegireva LS, Kornishina TL, Chikova IA, et al. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2015;13:4.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"725_CR17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/art.41488","volume":"73","author":"P Quartier","year":"2021","unstructured":"Quartier P, Alexeeva E, Constantin T, Chasnyk V, Wulffraat N, Palmblad K, et al. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb\/IV Open-Label. Randomized Study Arthritis Rheumatol. 2021;73(2):336\u201346. https:\/\/doi.org\/10.1002\/art.41488.","journal-title":"Randomized Study. Arthritis Rheumatol."},{"issue":"7","key":"725_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol. 2019;71(7):1163\u201373.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"725_CR19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034\u201343.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"725_CR20","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1997;40(7):1202\u20139.","journal-title":"Arthritis & Rheumatism: Official Journal of the American College of Rheumatology"},{"issue":"4","key":"725_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/acr.23709","volume":"71","author":"K Minden","year":"2019","unstructured":"Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, et al. Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. Arthritis Care Res (Hoboken). 2019;71(4):471\u201381.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"725_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00393-020-00779-2","volume":"79","author":"D Foll","year":"2020","unstructured":"Foll D, Wittkowski H, Hinze C. [Still\u2019s disease as biphasic disorder: Current knowledge on pathogenesis and novel treatment approaches]. Z Rheumatol. 2020;79(7):639\u201348.","journal-title":"Z Rheumatol"},{"key":"725_CR23","doi-asserted-by":"publisher","unstructured":"Liao C-H, Chiang B-L, Yang Y-H. Tapering of Biological Agents in Juvenile ERA Patients in Daily Clinical Practice. Front Med (Lausanne). 2021;8:665170. https:\/\/doi.org\/10.3389\/fmed.2021.665170. eCollection 2021.","DOI":"10.3389\/fmed.2021.665170"},{"issue":"3","key":"725_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3899\/jrheum.161078","volume":"44","author":"DB Horton","year":"2017","unstructured":"Horton DB, Onel KB, Beukelman T, Ringold S. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. J Rheumatol. 2017;44(3):352\u201360.","journal-title":"J Rheumatol"},{"issue":"12","key":"725_CR25","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/rheumatology\/keaa118","volume":"59","author":"A Chhabra","year":"2020","unstructured":"Chhabra A, Robinson C, Houghton K, Cabral DA, Morishita K, Tucker LB, et al. Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience. Rheumatology (Oxford). 2020;59(12):3727\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"725_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13075-019-2091-8","volume":"22","author":"A Henrey","year":"2020","unstructured":"Henrey A, Rypdal V, Rypdal M, Loughin T, Nordal E, Guzman J, et al. Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort. Arthritis Res Ther. 2020;22(1):10.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"725_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/BOR.0000000000000620","volume":"31","author":"J Guzman","year":"2019","unstructured":"Guzman J, Oen K, Loughin T. Predicting disease severity and remission in juvenile idiopathic arthritis: are we getting closer? Curr Opin Rheumatol. 2019;31(5):436\u201349.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"725_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","volume":"75","author":"J Guzman","year":"2016","unstructured":"Guzman J, Oen K, Huber AM, Watanabe Duffy K, Boire G, Shiff N, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Ann Rheum Dis. 2016;75(6):1092\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"725_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40272-019-00362-6","volume":"21","author":"O Halyabar","year":"2019","unstructured":"Halyabar O, Mehta J, Ringold S, Rumsey DG, Horton DB. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature. Pediatr Drugs. 2019;21(6):469\u201392.","journal-title":"Pediatr Drugs"},{"issue":"6","key":"725_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/humu.20720","volume":"29","author":"F Milhavet","year":"2008","unstructured":"Milhavet F, Cuisset L, Hoffman HM, Slim R, El-Shanti H, Aksentijevich I, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat. 2008;29(6):803\u20138.","journal-title":"Hum Mutat"},{"issue":"11","key":"725_CR31","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1136\/annrheumdis-2013-204991","volume":"74","author":"R Levy","year":"2015","unstructured":"Levy R, Gerard L, Kuemmerle-Deschner J, Lachmann HJ, Kone-Paut I, Cantarini L, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis. 2015;74(11):2043\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"725_CR32","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1002\/art.40208","volume":"69","author":"JB Kuemmerle-Deschner","year":"2017","unstructured":"Kuemmerle-Deschner JB, Verma D, Endres T, Broderick L, de Jesus AA, Hofer F, et al. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges. Arthritis Rheumatol. 2017;69(11):2233\u201340.","journal-title":"Arthritis Rheumatol"},{"key":"725_CR33","doi-asserted-by":"publisher","first-page":"568865","DOI":"10.3389\/fphar.2020.568865","volume":"11","author":"V Hentgen","year":"2020","unstructured":"Hentgen V, Kone-Paut I, Belot A, Galeotti C, Grateau G, Carbasse A, et al. Long-Term Follow-Up and Optimization of Interleukin-1 Inhibitors in the Management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort. Front Pharmacol. 2020;11:568865.","journal-title":"Front Pharmacol"},{"key":"725_CR34","first-page":"CD010455","volume":"5","author":"LM Verhoef","year":"2019","unstructured":"Verhoef LM, van den Bemt BJ, van der Maas A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, et al. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2019;5:CD010455.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"725_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13075-020-02165-4","volume":"22","author":"S Dierckx","year":"2020","unstructured":"Dierckx S, Sokolova T, Lauwerys BR, Avramovska A, de Bellefon LM, Toukap AN, et al. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort. Arthritis Res Ther. 2020;22(1):96.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"725_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-019-1943-6","volume":"21","author":"JW Park","year":"2019","unstructured":"Park JW, Kim HA, Shin K, Park YB, Kim TH, Song YW, et al. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study. Arthritis Res Ther. 2019;21(1):163.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"725_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12969-019-0342-5","volume":"17","author":"S Shenoi","year":"2019","unstructured":"Shenoi S, Nanda K, Schulert GS, Bohnsack JF, Cooper AM, Edghill B, et al. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey. Pediatr Rheumatol Online J. 2019;17(1):48.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"725_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12969-021-00495-4","volume":"19","author":"K Sorensen","year":"2021","unstructured":"Sorensen K, Skirbekk H, Kvarstein G, Woien H. I don\u2019t want to think about it: a qualitative study of children (6\u201318 years) with rheumatic diseases and parents\u2019 experiences with regular needle injections at home. Pediatr Rheumatol Online J. 2021;19(1):8.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"725_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40262-018-0680-3","volume":"58","author":"D Ternant","year":"2019","unstructured":"Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clin Pharmacokinet. 2019;58(2):169\u201387.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"725_CR40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40262-020-00874-2","volume":"59","author":"A Bensalem","year":"2020","unstructured":"Bensalem A, Ternant D. Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. Clin Pharmacokinet. 2020;59(7):857\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"725_CR41","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1136\/annrheumdis-2019-215546","volume":"79","author":"H Marotte","year":"2020","unstructured":"Marotte H, Rinaudo-Gaujous M, Petiet C, Fautrel B, Paul S. Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study. Ann Rheum Dis. 2020;79(7):e81.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"725_CR42","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00228-020-02925-w","volume":"76","author":"C Bastida","year":"2020","unstructured":"Bastida C, Huitema ADR, l\u2019Ami MJ, Ruiz-Esquide V, Wolbink GJ, Sanmarti R, et al. Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic\/pharmacodynamic simulations. Eur J Clin Pharmacol. 2020;76(10):1417\u201325.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"725_CR43","doi-asserted-by":"publisher","first-page":"e1043-56","DOI":"10.1097\/01.mjt.0000489921.28180.b9","volume":"23","author":"I Mahmood","year":"2016","unstructured":"Mahmood I. Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products. Am J Ther. 2016;23(4):e1043-56.","journal-title":"Am J Ther"},{"issue":"6","key":"725_CR44","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17425255.2018.1482278","volume":"14","author":"P Malik","year":"2018","unstructured":"Malik P, Edginton A. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2018;14(6):585\u201399.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"725_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12969-021-00514-4","volume":"19","author":"T Welzel","year":"2021","unstructured":"Welzel T, Winskill C, Zhang N, Woerner A, Pfister M. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J. 2021;19(1):46.","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-022-00725-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T12:58:00Z","timestamp":1664974680000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-022-00725-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1186\/s12969-022-00725-3","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"19 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to correct the funding information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval needed (Independent Research Ethics Committee Tuebingen; 113\/2022A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JBKD received grant support and speaker\u2019s fees from Novartis and SOBI. SMB has attended ad boards and has given invited presentations for Novartis, SOBI and AbbVie (no honorarium). TW has given invited presentation for Novartis (no honorarium). LO has nothing to declare. MT has attended ad boards for Novartis and SOBI (no honorarium). MP is a part-time consultant at Certara.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"67"}}